Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
- PMID: 34606578
- PMCID: PMC8491132
- DOI: 10.1001/jama.2021.18178
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
Abstract
Importance: The evidence for benefit of convalescent plasma for critically ill patients with COVID-19 is inconclusive.
Objective: To determine whether convalescent plasma would improve outcomes for critically ill adults with COVID-19.
Design, setting, and participants: The ongoing Randomized, Embedded, Multifactorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) enrolled and randomized 4763 adults with suspected or confirmed COVID-19 between March 9, 2020, and January 18, 2021, within at least 1 domain; 2011 critically ill adults were randomized to open-label interventions in the immunoglobulin domain at 129 sites in 4 countries. Follow-up ended on April 19, 2021.
Interventions: The immunoglobulin domain randomized participants to receive 2 units of high-titer, ABO-compatible convalescent plasma (total volume of 550 mL ± 150 mL) within 48 hours of randomization (n = 1084) or no convalescent plasma (n = 916).
Main outcomes and measures: The primary ordinal end point was organ support-free days (days alive and free of intensive care unit-based organ support) up to day 21 (range, -1 to 21 days; patients who died were assigned -1 day). The primary analysis was an adjusted bayesian cumulative logistic model. Superiority was defined as the posterior probability of an odds ratio (OR) greater than 1 (threshold for trial conclusion of superiority >99%). Futility was defined as the posterior probability of an OR less than 1.2 (threshold for trial conclusion of futility >95%). An OR greater than 1 represented improved survival, more organ support-free days, or both. The prespecified secondary outcomes included in-hospital survival; 28-day survival; 90-day survival; respiratory support-free days; cardiovascular support-free days; progression to invasive mechanical ventilation, extracorporeal mechanical oxygenation, or death; intensive care unit length of stay; hospital length of stay; World Health Organization ordinal scale score at day 14; venous thromboembolic events at 90 days; and serious adverse events.
Results: Among the 2011 participants who were randomized (median age, 61 [IQR, 52 to 70] years and 645/1998 [32.3%] women), 1990 (99%) completed the trial. The convalescent plasma intervention was stopped after the prespecified criterion for futility was met. The median number of organ support-free days was 0 (IQR, -1 to 16) in the convalescent plasma group and 3 (IQR, -1 to 16) in the no convalescent plasma group. The in-hospital mortality rate was 37.3% (401/1075) for the convalescent plasma group and 38.4% (347/904) for the no convalescent plasma group and the median number of days alive and free of organ support was 14 (IQR, 3 to 18) and 14 (IQR, 7 to 18), respectively. The median-adjusted OR was 0.97 (95% credible interval, 0.83 to 1.15) and the posterior probability of futility (OR <1.2) was 99.4% for the convalescent plasma group compared with the no convalescent plasma group. The treatment effects were consistent across the primary outcome and the 11 secondary outcomes. Serious adverse events were reported in 3.0% (32/1075) of participants in the convalescent plasma group and in 1.3% (12/905) of participants in the no convalescent plasma group.
Conclusions and relevance: Among critically ill adults with confirmed COVID-19, treatment with 2 units of high-titer, ABO-compatible convalescent plasma had a low likelihood of providing improvement in the number of organ support-free days.
Trial registration: ClinicalTrials.gov Identifier: NCT02735707.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8491132/bin/jama-e2118178-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8491132/bin/jama-e2118178-g002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8491132/bin/jama-e2118178-g003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8491132/bin/jama-e2118178-g004.gif)
Similar articles
-
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910. JAMA. 2022. PMID: 35315874 Free PMC article. Clinical Trial.
-
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.JAMA. 2020 Oct 6;324(13):1317-1329. doi: 10.1001/jama.2020.17022. JAMA. 2020. PMID: 32876697 Free PMC article. Clinical Trial.
-
Intravenous Vitamin C for Patients Hospitalized With COVID-19: Two Harmonized Randomized Clinical Trials.JAMA. 2023 Nov 14;330(18):1745-1759. doi: 10.1001/jama.2023.21407. JAMA. 2023. PMID: 37877585 Free PMC article.
-
Convalescent plasma for people with COVID-19: a living systematic review.Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2023 May 10;5:CD013600. doi: 10.1002/14651858.CD013600.pub6. PMID: 36734509 Free PMC article. Updated. Review.
-
Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review.JAMA. 2024 Jul 23;332(4):318-328. doi: 10.1001/jama.2024.6096. JAMA. 2024. PMID: 38865154 Review.
Cited by
-
Exploring Study Design Foibles in Randomized Controlled Trials on Convalescent Plasma in Hospitalized COVID-19 Patients.Life (Basel). 2024 Jun 22;14(7):792. doi: 10.3390/life14070792. Life (Basel). 2024. PMID: 39063547 Free PMC article. Review.
-
Automatic Population of the Case Report Forms for an International Multifactorial Adaptive Platform Trial Amid the COVID-19 Pandemic.AMIA Jt Summits Transl Sci Proc. 2024 May 31;2024:276-284. eCollection 2024. AMIA Jt Summits Transl Sci Proc. 2024. PMID: 38827056 Free PMC article.
-
Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.JAMA Intern Med. 2024 Jul 1;184(7):769-777. doi: 10.1001/jamainternmed.2024.0581. JAMA Intern Med. 2024. PMID: 38739397
-
Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19.World J Stem Cells. 2024 Apr 26;16(4):353-374. doi: 10.4252/wjsc.v16.i4.353. World J Stem Cells. 2024. PMID: 38690515 Free PMC article. Review.
-
Acute Respiratory Failure From Early Pandemic COVID-19: Noninvasive Respiratory Support vs Mechanical Ventilation.CHEST Crit Care. 2024 Mar;2(1):100030. doi: 10.1016/j.chstcc.2023.100030. Epub 2023 Nov 24. CHEST Crit Care. 2024. PMID: 38645483 Free PMC article.
References
-
- Angus DC, Derde L, Al-Beidh F, et al. ; Writing Committee for the REMAP-CAP Investigators . Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317-1329. doi:10.1001/jama.2020.17022 - DOI - PMC - PubMed
-
- Sterne JAC, Murthy S, Diaz JV, et al. ; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group . Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330-1341. doi:10.1001/jama.2020.17023 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous